Cynapsus Therapeutics Inc. (CTH)(製薬・医療分野):企業M&A動向

◆英語タイトル:Cynapsus Therapeutics Inc. (CTH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:GDPH167661D
◆発行会社(調査会社):GlobalData
◆発行日:2015年3月16日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary

Cynapsus Therapeutics Inc. (Cynapsus) is a specialty pharmaceutical company. It discovers and develops non-injectable delivery of the only approved drugs for the treatment of symptoms of Parkinson’s disease. The drug candidate of the company APL-130277 is a fast-acting reformulation of apomorphine, which is used as rescue therapy to treat motor fluctuations in patients with Parkinson’s disease. Cynapsus discovers disease modifying therapies for chronic brain conditions of Parkinson’s disease, neuropathic pain associated with multiple sclerosis and cancer, and nausea and vomiting and appetite stimulation, among others. Cynapsus markets its products in the US, Europe, Japan and other countries. The company was formerly known as Cannasat Therapeutics Inc. Cynapsus is headquartered in Toronto, Ontario, Canada.

Cynapsus Therapeutics Inc. (CTH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 9
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Cynapsus Therapeutics Terminates Option For Licensing Agreement With Adagio For APL-130277 10
IntelGenx Enters Licensing Agreement With Cannasat Therapeutics 12
Cannasat Therapeutics Enters Into Licensing Option Agreement With Adagio Pharma 14
Equity Offering 15
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 15
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 17
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 19
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 20
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 22
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.29 Million 23
Cannasat Therapeutics Terminates Private Placement Of US$2.5 Million 24
Cannasat Therapeutics Completes First Tranche Of Public Offering 26
Cannasat Therapeutics Completes Private Placement Of US$0.31 Million 28
Debt Offering 29
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 29
Cynapsus Therapeutics Completes Public Offering Of Secured Series D Debentures For US$0.51 Million 31
Cynapsus Therapeutics Completes Public Offering Of Secured Series C Debentures For US$0.3 Million 32
Cynapsus Therapeutics Completes Public Offering Of 8% Secured Series B Debenture For US$0.1 Million 33
Cynapsus Therapeutics Completes Private Placement Of 8% Secured Debentures For US$0.7 Million 34
Acquisition 35
Cynapsus Therapeutics Completes Acquisition Of Adagio Pharma 35
Cynapsus Therapeutics Inc. – Key Competitors 37
Key Employees 38
Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Key Facts, 2013 1
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
Cynapsus Therapeutics Inc., Deals By Therapy Area, 2009 to YTD 2015 8
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 9
Cynapsus Therapeutics Terminates Option For Licensing Agreement With Adagio For APL-130277 10
IntelGenx Enters Licensing Agreement With Cannasat Therapeutics 12
Cannasat Therapeutics Enters Into Licensing Option Agreement With Adagio Pharma 14
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 15
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 17
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 19
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 20
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 22
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.29 Million 23
Cannasat Therapeutics Terminates Private Placement Of US$2.5 Million 24
Cannasat Therapeutics Completes First Tranche Of Public Offering 26
Cannasat Therapeutics Completes Private Placement Of US$0.31 Million 28
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 29
Cynapsus Therapeutics Completes Public Offering Of Secured Series D Debentures For US$0.51 Million 31
Cynapsus Therapeutics Completes Public Offering Of Secured Series C Debentures For US$0.3 Million 32
Cynapsus Therapeutics Completes Public Offering Of 8% Secured Series B Debenture For US$0.1 Million 33
Cynapsus Therapeutics Completes Private Placement Of 8% Secured Debentures For US$0.7 Million 34
Cynapsus Therapeutics Completes Acquisition Of Adagio Pharma 35
Cynapsus Therapeutics Inc., Key Competitors 37
Cynapsus Therapeutics Inc., Key Employees 38
Cynapsus Therapeutics Inc., Subsidiaries 39

List of Figures
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 1
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 1
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 1
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 6
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
Cynapsus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8

★海外企業調査レポート[Cynapsus Therapeutics Inc. (CTH)(製薬・医療分野):企業M&A動向]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • FTI Consulting, Inc. (FCN):企業財務及び戦略的SWOT分析
    Summary FTI Consulting, Inc. (FTI) is a business and consumer services company that offers corporate finance services. The company offers corporate finance and restructuring, economic consulting, forensic and litigation consulting, strategic communications and technology services among others. It of …
  • Transasia Bio-Medicals Ltd-医療機器分野:企業M&A・提携分析
    Summary Transasia Bio-Medicals Ltd (Transasia), a subsidiary of Erba Diagnostics Mannheim GmbH is an in-vitro diagnostic company that manufactures and exports diagnostic instruments and reagents. The company offers its products in various categories including clinical chemistry, immunology, diabetes …
  • Renesas Electronics Corporation:企業の戦略・SWOT・財務分析
    Renesas Electronics Corporation - Strategy, SWOT and Corporate Finance Report Summary Renesas Electronics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Monash Health:企業の戦略・SWOT・財務分析
    SummaryMonash Health - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings …
  • Harvest Technologies Corporation:(医療機器分野)企業M&A及び提携動向
    Summary Harvest Technologies Corporation (HTC) is a medical device manufacturer. The company designs, develops, manufactures and markets products for the cardiovascular and orthopedic market. Its products include bone marrow aspirate concentrate system, bone graft applicators, and SmartPReP system. …
  • Credito Emiliano SpA:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Credito Emiliano SpA Mergers an …
  • Islet Sciences Inc (ISLT):企業財務及び戦略的SWOT分析
    Summary Islet Sciences Inc (Islet Sciences) pharmaceutical company that develops medicines and technologies for the treatment of metabolic diseases. The company pipeline includes immune modulating small molecule interleukin 12 inhibitors to address disorders associated with inflammation. It offers c …
  • Green Dragon Gas Ltd. (GDG):企業財務及び戦略的SWOT分析
    Summary Green Dragon Gas Ltd. (Green Dragon) is an oil and gas company that offers exploration and production of coal bed methane gas. The company provides transportation fleet, retail CNG station, exploration, and production programs, among others. It offers an alternative to petrol and diesel like …
  • American Electric Technologies, Inc. (AETI):企業のM&A・提携動向(石油・ガス分野)
    Summary American Electric Technologies, Inc. (AETI) is a power delivery solution company that provides solution to the traditional and renewable energy sectors. The company provides products that include power distribution and power conversion products. Its power distribution products comprise low v …
  • KFx Medical Corporation:(医療機器分野)企業M&A及び提携動向
    Summary KFx Medical Corporation (KFx) is a medical device company. The company develops and manufactures soft tissue fixation implants for orthopedic sports medicine surgeons. It provides arthrocopic, subpectoral and lower extremity products. KFx develops technologies that improve lower extremity pr …
  • AxoGen, Inc. (AXGN):企業の財務及び戦略的SWOT分析
    Summary AxoGen, Inc. (AxoGen) is a medical technology company that provides solutions to repair and protect peripheral nerves. The company offers products that include AxoTouch two-point discriminator, AxoGuard nerve Connector, Avance nerve graft, and AxoGuard nerve protector. It also provides clini …
  • Silver Wheaton Corp.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Silver Wheaton Corp. Mergers an …
  • Asatsu-DK Inc. (9747):企業の財務・戦略的SWOT分析
    Asatsu-DK Inc. (9747) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • La Plata Electric Association, Inc.:企業の発電所・SWOT分析2018
    La Plata Electric Association, Inc. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • EDF Energy Renewables:企業のM&A・提携動向(エネルギー分野)
    Summary EDF Energy Renewables (EDF Energy), a subsidiary of EDF Group is a renewable energy company that generates electricity from renewable power sources such as wind. The company offers services such as development, construction, production and operation and maintenance of wind farms. It operates …
  • CEVA Group PLC:企業の戦略・SWOT・財務分析
    SummaryCEVA Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings …
  • CBIZ, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' CBIZ, Inc. Mergers and Acquisit …
  • Tata Motors Ltd (TATAMOTORS):企業の財務・戦略的SWOT分析
    Tata Motors Ltd (TATAMOTORS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • TerniEnergia SpA (TER):企業財務及び戦略的SWOT分析
    Summary TerniEnergia SpA (TerniEnergia), a subsidiary of Terni Research S.p.A., is an energy company that operates in the fields of renewable energy, energy efficiency, waste and energy management. The company operates in two sectors namely the environmental sector and the waste to energy (WTE) sect …
  • TowneBank:企業の戦略・SWOT・財務分析
    SummaryTowneBank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings - De …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆